Nama's AI scorecard currently rates Establishment Labs Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ESTA report earnings?

Establishment Labs's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.16.

What is the ESTA price target?

The median analyst price target from 10 analysts is $95.00, with a range of $90.00 – $105.00.

Is ESTA Shariah compliant?

Nama's AAOIFI-style screen reads Establishment Labs as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Establishment Labs (ESTA)

Healthcare · Medical Devices · NASDAQ

Establishment Labs (ESTA) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $2.00B and a free-cash-flow yield of -2.9%. Over the most recent reported fiscal year, revenue grew 27.1%. Nama's AI scorecard rates it Sell, 3.1 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -1.6% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-31.3%

How far the last close sits under the highest price of the past five years.

Market cap	$2.00B
Trailing P/E	—
Price / book	91.8
Price / sales	7.6
FCF yield	-2.9%
Dividend yield	—
Gross margin	70.5%
Operating margin	-7.6%
Net margin	-15.8%
Revenue growth (YoY)	+27.1%
Revenue growth (3-yr annual)	+9.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.1
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Devices

ESTA earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$0.16). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	-$0.35	-$0.23	-52.2%	—
Q2 2026	Aug 6, 2026	-$0.39	-$0.30	-30.0%	$67.54M
Q1 2026	May 6, 2026	-$0.45	-$0.38	-18.4%	$59.88M
Q4 2025	Feb 24, 2026	-$0.09	-$0.21	+57.1%	$64.62M

ESTA analyst price target

Median target $95.00 from 10 analysts, ranging $90.00 – $105.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live ESTA data on Nama Insights →

ESTA FAQ

Is ESTA a buy?: Nama's AI scorecard currently rates Establishment Labs Sell (3.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ESTA report earnings?: Establishment Labs's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.16.
What is the ESTA price target?: The median analyst price target from 10 analysts is $95.00, with a range of $90.00 – $105.00.
Is ESTA Shariah compliant?: Nama's AAOIFI-style screen reads Establishment Labs as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.